Loading...
Header Logo
Keywords
Last Name
Institution

PETER F THALL

TitleProfessor
InstitutionMD Anderson
DepartmentBiostatistics
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Boulet S, Ursino M, Thall P, Jannot AS, Zohar S. Bayesian variable selection based on clinical relevance weights in small sample studies-Application to colon cancer. Stat Med. 2019 Jan 22. PMID: 30672015.
      View in: PubMed
    2. Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, Khatua S, Ketonen L, Fontanilla H, McGovern SL. A Phase 1/2 Trial of Reirradiation for Diffuse Intrinsic Pontine Glioma. Int J Radiat Oncol Biol Phys. 2019 Jan 02. PMID: 30610915.
      View in: PubMed
    3. Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplant. 2018 Dec 10. PMID: 30532055.
      View in: PubMed
    4. Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018 Nov 02; 9(86):35611-35622. PMID: 30479692.
      View in: PubMed
    5. Chapple AG, Thall PF. A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III. Biometrics. 2018 Oct 26. PMID: 30367457.
      View in: PubMed
    6. Murray TA, Yuan Y, Thall PF. A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes. J Am Stat Assoc. 2018; 113(523):1255-1267. PMID: 30739965.
      View in: PubMed
    7. Chapple AG, Thall PF. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination. Pharm Stat. 2018 11; 17(6):734-749. PMID: 30112806.
      View in: PubMed
    8. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2018 Jul 22; 1-11. PMID: 30032678.
      View in: PubMed
    9. Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan EC. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res. 2018 Sep 01; 24(17):4098-4109. PMID: 29769208.
      View in: PubMed
    10. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 Aug; 24(8):1602-1609. PMID: 29501779.
      View in: PubMed
    11. Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol. 2018 03 01; 29(3):694-699. PMID: 29267863.
      View in: PubMed
    12. Murray TA, Yuan Y, Thall PF, Elizondo JH, Hofstetter WL. A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics. 2018 09; 74(3):1095-1103. PMID: 29359314.
      View in: PubMed
    13. Thall PF, Ursino M, Baudouin V, Alberti C, Zohar S. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Stat Methods Med Res. 2019 Feb; 28(2):404-418. PMID: 28870123.
      View in: PubMed
    14. Thall PF, Mueller P, Xu Y, Guindani M. Bayesian nonparametric statistics: A new toolkit for discovery in cancer research. Pharm Stat. 2017 11; 16(6):414-423. PMID: 28677272.
      View in: PubMed
    15. Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. J Am Stat Assoc. 2017; 112:11-23. PMID: 28943681.
      View in: PubMed
    16. Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol. 2017 06; 123(3):376-381. PMID: 28455153.
      View in: PubMed
    17. Chapple AG, Vannucci M, Thall PF, Lin S. Bayesian variable selection for a semi-competing risks model with three hazard functions. Comput Stat Data Anal. 2017 Aug; 112:170-185. PMID: 29033478.
      View in: PubMed
    18. Wathen JK, Thall PF. A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clin Trials. 2017 Oct; 14(5):432-440. PMID: 28982263.
      View in: PubMed
    19. Morita S, Thall PF, Takeda K. A simulation study of methods for selecting subgroup-specific doses in phase 1 trials. Pharm Stat. 2017 03; 16(2):143-156. PMID: 28111916.
      View in: PubMed
    20. Müller P, Xu Y, Thall PF. Clinical Trial Design as a Decision Problem. Appl Stoch Models Bus Ind. 2017 May-Jun; 33(3):296-301. PMID: 29200977.
      View in: PubMed
    21. Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant. 2017 Apr; 52(4):580-587. PMID: 27991894.
      View in: PubMed
    22. Xu Y, Müller P, Wahed AS, Thall PF. Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times. J Am Stat Assoc. 2016; 111(515):921-935. PMID: 28018015.
      View in: PubMed
    23. Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017 03; 31(3):697-704. PMID: 27654852.
      View in: PubMed
    24. He L, Chapple A, Liao Z, Komaki R, Thall PF, Lin SH. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiother Oncol. 2016 10; 121(1):70-74. PMID: 27562616.
      View in: PubMed
    25. Xu Y, Thall PF, Müller P, Mehran RJ. A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling. Bayesian Anal. 2017; 12(3):639-652. PMID: 28959372.
      View in: PubMed
    26. Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine?±?Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2016 10; 22(10):1792-1800. PMID: 27377901; PMCID: PMC5026955 [Available on 10/01/17].
    27. Thall PF, Nguyen HQ, Zinner RG. Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes. J R Stat Soc Ser C Appl Stat. 2017 Jan; 66(1):201-224. PMID: 28255183.
      View in: PubMed
    28. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8. PMID: 27203405.
      View in: PubMed
    29. Murray TA, Thall PF, Yuan Y. Utility-based designs for randomized comparative trials with categorical outcomes. Stat Med. 2016 10 30; 35(24):4285-4305. PMID: 27189672.
      View in: PubMed
    30. Lee J, Thall PF, Ji Y, Müller P. A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics. 2016 Apr; 17(2):304-19. PMID: 26553915.
      View in: PubMed
    31. Hobbs BP, Thall PF, Lin SH. Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. J R Stat Soc Ser C Appl Stat. 2016 Feb; 65(2):273-297. PMID: 27034510.
      View in: PubMed
    32. Sandberg DI, Rytting M, Zaky W, Kerr M, Ketonen L, Kundu U, Moore BD, Yang G, Hou P, Sitton C, Cooper LJ, Gopalakrishnan V, Lee DA, Thall PF, Khatua S. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial. J Neurooncol. 2015 Oct; 125(1):133-41. PMID: 26255071.
      View in: PubMed
    33. Tseng WW, Zhou S, To CA, Thall PF, Lazar AJ, Pollock RE, Lin PP, Cormier JN, Lewis VO, Feig BW, Hunt KK, Ballo MT, Patel S, Pisters PW. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer. 2015 Oct 15; 121(20):3659-67. PMID: 26177983.
      View in: PubMed
    34. Huang X, Choi S, Wang L, Thall PF. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data. Stat Med. 2015 Nov 20; 34(26):3424-43. PMID: 26095711.
      View in: PubMed
    35. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20. PMID: 26071868; PMCID: PMC4781754 [Available on 11/01/16].
    36. Lee J, Thall PF, Ji Y, Müller P. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity. J Am Stat Assoc. 2015 Jun 01; 110(510):711-722. PMID: 26366026.
      View in: PubMed
    37. Thall P, Fox P, Wathen J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Ann Oncol. 2015 Aug; 26(8):1621-8. PMID: 25979922.
      View in: PubMed
    38. Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1392-8. PMID: 25985919; PMCID: PMC4506716.
    39. Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant. 2015 Jul; 50(7):939-946. PMID: 25867648.
      View in: PubMed
    40. Wang J, Milton DR, He L, Komaki R, Liao Z, Crane CH, Minsky BD, Thall PF, Lin SH. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol. 2015 Mar; 10(3):518-26. PMID: 25695222; PMCID: PMC4335306.
    41. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015 Sep; 29(9):1945-8. PMID: 25721897; PMCID: PMC4785590.
    42. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34. PMID: 25682597; PMCID: PMC4486227.
    43. Graziani R, Guindani M, Thall PF. Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome. Biometrics. 2015 Mar; 71(1):188-197. PMID: 25319212; PMCID: PMC4383707.
    44. Wang L, Shen J, Thall PF. A Modified Adaptive Lasso for Identifying Interactions in the Cox Model with the Heredity Constraint. Stat Probab Lett. 2014 Oct 01; 93:126-133. PMID: 25071299.
      View in: PubMed
    45. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 01; 32(31):3497-505. PMID: 25267759; PMCID: PMC4209101.
    46. Thall PF, Herrick RC, Nguyen HQ, Venier JJ, Norris JC. Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding. Clin Trials. 2014 Dec; 11(6):657-66. PMID: 25179541; PMCID: PMC4229398.
    47. Thall PF, Nguyen HQ, Zohar S, Maton P. Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. J Am Stat Assoc. 2014 Sep 01; 109(507):931-943. PMID: 25368435.
      View in: PubMed
    48. Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS. Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1139-44. PMID: 24727332; PMCID: PMC4099297.
    49. Jin IH, Liu S, Thall PF, Yuan Y. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. J Am Stat Assoc. 2014; 109(506):525-536. PMID: 25382884.
      View in: PubMed
    50. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9. PMID: 23975663.
      View in: PubMed
    51. Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics. 2013 Sep; 69(3):673-82. PMID: 23957592; PMCID: PMC3963428.
    52. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8. PMID: 23872222; PMCID: PMC4157818.
    53. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30. PMID: 23649003; PMCID: PMC3699964.
    54. David E, Thall PF, Kalhor N, Hofstetter WL, Rice DC, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Wei C, Mehran RJ. Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size. Ann Thorac Surg. 2013 Jun; 95(6):1872-7; discussion 1877. PMID: 23643547; PMCID: PMC4365776.
    55. Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant. 2013 Sep; 48(9):1218-23. PMID: 23503529; PMCID: PMC4010139.
    56. Wahed AS, Thall PF. Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia. J R Stat Soc Ser C Appl Stat. 2013 Jan; 62(1):67-83. PMID: 24014891.
      View in: PubMed
    57. Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt S. Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biol Blood Marrow Transplant. 2013 Mar; 19(3):474-80. PMID: 23220013; PMCID: PMC4052712.
    58. Morita S, Thall PF, Müller P. Prior Effective Sample Size in Conditionally Independent Hierarchical Models. Bayesian Anal. 2012 Sep; 7(3). PMID: 24175005.
      View in: PubMed
    59. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85. PMID: 22867894; PMCID: PMC3923623.
    60. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant. 2013 Jan; 48(1):26-31. PMID: 22732703; PMCID: PMC4346146.
    61. Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer. J Am Stat Assoc. 2012 Jun; 107(498):493-508. PMID: 22956855.
      View in: PubMed
    62. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86. PMID: 22643322; PMCID: PMC4010147.
    63. Thall PF, Nguyen HQ, Wang X, Wolff JE. A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity. J Stat Plan Inference. 2012 Apr 01; 142(4):944-955. PMID: 22228921.
      View in: PubMed
    64. Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Rejoinder to comments on Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer. J Am Stat Assoc. 2012; 107(498):518-520. PMID: 24489418.
      View in: PubMed
    65. Yuan Y, Thall PF, Wolff JE. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. J R Stat Soc Ser C Appl Stat. 2012 Jan 01; 61(1):135-149. PMID: 22408277.
      View in: PubMed
    66. Thall PF, Nguyen HQ. Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. J Biopharm Stat. 2012; 22(4):785-801. PMID: 22651115; PMCID: PMC3385658.
    67. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012 Jul 15; 118(14):3549-55. PMID: 22086552; PMCID: PMC4038445.
    68. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011 Nov 24; 118(22):5957-64. PMID: 21967975; PMCID: PMC3761379.
    69. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15. PMID: 21887685; PMCID: PMC4015116.
    70. Wolff JE, Rytting M, Vats T, Ater J, Mahajan A, Woo S, Ketonen L, Kuttesch J, Liu D, Thall P, Chang EL. Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center. Anticancer Res. 2011 Jun; 31(6):2265-9. PMID: 21737651.
      View in: PubMed
    71. Thall PF, Liu DD, Berrak SG, Wolff JE. Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapies. Stat Med. 2011 Jul 10; 30(15):1777-94. PMID: 21590700; PMCID: PMC3115413.
    72. Thall PF, Szabo A, Nguyen HQ, Amlie-Lefond CM, Zaidat OO. Optimizing the concentration and bolus of a drug delivered by continuous infusion. Biometrics. 2011 Dec; 67(4):1638-46. PMID: 21401568; PMCID: PMC3137757.
    73. Mathew P, Wen S, Morita S, Thall PF. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. J Interferon Cytokine Res. 2011 Jul; 31(7):539-44. PMID: 21323568; PMCID: PMC3163391.
    74. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900. PMID: 20946966; PMCID: PMC3760472.
    75. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant. 2011 Mar; 17(3):412-20. PMID: 20674757; PMCID: PMC4031688.
    76. de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010 Dec 01; 116(23):5420-31. PMID: 20672358.
      View in: PubMed
    77. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20; 28(24):3851-7. PMID: 20625118; PMCID: PMC2940402.
    78. Morita S, Thall PF, Müller P. Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics. Stat Biosci. 2010 Jul 01; 2(1):1-17. PMID: 20668651.
      View in: PubMed
    79. Thall PF. Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials. Stat Sci. 2010 May; 25(2):227-244. PMID: 21318084.
      View in: PubMed
    80. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010 Feb 15; 116(4):814-21. PMID: 20052721; PMCID: PMC3806193.
    81. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009 Oct 27; 88(8):1019-24. PMID: 19855248; PMCID: PMC4324621.
    82. Morita S, Thall PF, Bekele BN, Mathew P. A Bayesian hierarchical mixture model for platelet derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. J R Stat Soc Ser C Appl Stat. 2009 Sep 03; 59(1):19-34. PMID: 20390057.
      View in: PubMed
    83. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1431-8. PMID: 19822303; PMCID: PMC4067765.
    84. Houede N, Thall PF, Nguyen H, Paoletti X, Kramar A. Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics. 2010 Jun; 66(2):532-40. PMID: 19673865; PMCID: PMC2893272.
    85. Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JEA. Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol. 2009 Dec; 95(3):383-392. PMID: 19543851.
      View in: PubMed
    86. Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol. 2009 Jun; 21 Suppl 1:S11-5. PMID: 19561406; PMCID: PMC4037323.
    87. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009 Jun 01; 27(16):2592-7. PMID: 19414678.
      View in: PubMed
    88. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20. PMID: 19244175; PMCID: PMC2734116.
    89. Norman PH, Thall PF, Purugganan RV, Riedel BJ, Thakar DR, Rice DC, Huynh L, Qiao W, Wen S, Smythe WR. A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Cancer. 2009 Feb 15; 115(4):833-41. PMID: 19130460.
      View in: PubMed
    90. Thall PF. Discussion on "A Hybrid Selection and Testing Procedure with Curtailment for Comparative Clinical Trials" by Elena M. Buzaianu and Pinyuen Chen. Seq Anal. 2009 Jan 01; 28(1):41-43. PMID: 20622929.
      View in: PubMed
    91. Wathen JK, Thall PF. Bayesian adaptive model selection for optimizing group sequential clinical trials. Stat Med. 2008 Nov 29; 27(27):5586-604. PMID: 18752257.
      View in: PubMed
    92. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan; 181(1):81-7; discussion 87. PMID: 19012911.
      View in: PubMed
    93. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009 Apr; 16(4):910-9. PMID: 18953611.
      View in: PubMed
    94. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ, Lin SH, Fidler IJ. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer. 2008 Nov 04; 99(9):1426-32. PMID: 18841158; PMCID: PMC2579696.
    95. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872. PMID: 18635226; PMCID: PMC4167838.
    96. Whelan HT, Cook JD, Amlie-Lefond CM, Hovinga CA, Chan AK, Ichord RN, Deveber GA, Thall PF. Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children. Stroke. 2008 Sep; 39(9):2627-36. PMID: 18617665.
      View in: PubMed
    97. Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Stat Med. 2008 Jul 10; 27(15):2802-15. PMID: 17948869.
      View in: PubMed
    98. Thall PF, Wathen JK. Bayesian designs to account for patient heterogeneity in phase II clinical trials. Curr Opin Oncol. 2008 Jul; 20(4):407-11. PMID: 18525336.
      View in: PubMed
    99. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84. PMID: 18489993; PMCID: PMC4230823.
    100. Thall PF, Nguyen HQ, Estey EH. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics. 2008 Dec; 64(4):1126-36. PMID: 18355387.
      View in: PubMed
    101. Thall PF. Some Geometric Methods for Constructing Decision Criteria Based On Two-Dimensional Parameters. J Stat Plan Inference. 2008; 138(2):516-527. PMID: 18617987.
      View in: PubMed
    102. Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics. 2008 Jul; 9(3):442-57. PMID: 18084008; PMCID: PMC3294317.
    103. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med. 2007 Nov 20; 26(26):4687-702. PMID: 17427204.
      View in: PubMed
    104. McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6727-34. PMID: 18006774.
      View in: PubMed
    105. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64. PMID: 17989720.
      View in: PubMed
    106. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate. 2007 Nov 01; 67(15):1677-85. PMID: 17879948.
      View in: PubMed
    107. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2007 Nov 07; 99(21):1613-22. PMID: 17971530.
      View in: PubMed
    108. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24. PMID: 17908974.
      View in: PubMed
    109. Thall PF. A review of phase 2-3 clinical trial designs. Lifetime Data Anal. 2008 Mar; 14(1):37-53. PMID: 17763973.
      View in: PubMed
    110. Morita S, Thall PF, Müller P. Determining the effective sample size of a parametric prior. Biometrics. 2008 Jun; 64(2):595-602. PMID: 17764481; PMCID: PMC3081791.
    111. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007 Jul 01; 25(19):2755-63. PMID: 17602081.
      View in: PubMed
    112. Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer. 2007 Mar; 43(5):859-66. PMID: 17306975; PMCID: PMC2030491.
    113. Braun TM, Thall PF, Nguyen H, de Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials. 2007; 4(2):113-24. PMID: 17456511.
      View in: PubMed
    114. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 01; 107(9):2254-61. PMID: 17029276.
      View in: PubMed
    115. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer. 2006 Apr 01; 106(7):1617-23. PMID: 16518826.
      View in: PubMed
    116. Thall PF, Wooten LH, Shpall EJ. A geometric approach to comparing treatments for rapidly fatal diseases. Biometrics. 2006 Mar; 62(1):193-201. PMID: 16542246.
      View in: PubMed
    117. Thall PF, Estey EH, Markman M. Some ethical issues in phase II trials in acute leukemia. Clin Adv Hematol Oncol. 2006 Feb; 4(2):95. PMID: 16739255.
      View in: PubMed
    118. Cheung YK, Inoue LY, Wathen JK, Thall PF. Continuous Bayesian adaptive randomization based on event times with covariates. Stat Med. 2006 Jan 15; 25(1):55-70. PMID: 16025549.
      View in: PubMed
    119. Thall PF, Cook JD, Estey EH. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations. J Biopharm Stat. 2006; 16(5):623-38. PMID: 17037262.
      View in: PubMed
    120. Thall PF, Estey EH. Some ethical issues in phase II trials in acute leukemia. Clin Adv Hematol Oncol. 2005 Dec; 3(12):943-8. PMID: 16555436.
      View in: PubMed
    121. Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Stat Med. 2005 Jul 15; 24(13):1947-64. PMID: 15806621.
      View in: PubMed
    122. Braun TM, Yuan Z, Thall PF. Determining a maximum-tolerated schedule of a cytotoxic agent. Biometrics. 2005 Jun; 61(2):335-43. PMID: 16011679.
      View in: PubMed
    123. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2):108-14. PMID: 15682071.
      View in: PubMed
    124. Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials. 2005; 2(6):467-78. PMID: 16422307.
      View in: PubMed
    125. Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004 Nov 15; 22(22):4567-74. PMID: 15542808.
      View in: PubMed
    126. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004 Sep; 60(3):684-93. PMID: 15339291.
      View in: PubMed
    127. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004 Aug 15; 22(16):3323-9. PMID: 15310776.
      View in: PubMed
    128. Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, Hunt KK, Yasko AW, Lin PP, Jacobson MG, Burgess MA, Pollock RE, Zagars GK, Benjamin RS, Ballo MT. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol. 2004 Aug 15; 22(16):3375-80. PMID: 15310783.
      View in: PubMed
    129. Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant. 2004 Jun; 33(12):1191-9. PMID: 15122310.
      View in: PubMed
    130. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004 May 01; 10(9):2968-76. PMID: 15131032.
      View in: PubMed
    131. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 01; 104(3):857-64. PMID: 15073038.
      View in: PubMed
    132. Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant. 2003 Nov; 9(11):722-4. PMID: 14682302.
      View in: PubMed
    133. Thall PF, Millikan RE, Mueller P, Lee SJ. Dose-finding with two agents in Phase I oncology trials. Biometrics. 2003 Sep; 59(3):487-96. PMID: 14601749.
      View in: PubMed
    134. Estey EH, Thall PF, Wang X, Verstovsek S, Cortes J, Kantarjian HM. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood. 2003 Nov 01; 102(9):3097-9. PMID: 12842982.
      View in: PubMed
    135. Thall PF, Lee SJ. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer. 2003 May-Jun; 13(3):251-61. PMID: 12801254.
      View in: PubMed
    136. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May; 121(4):578-85. PMID: 12752098.
      View in: PubMed
    137. Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med. 2003 Mar 15; 22(5):763-80. PMID: 12587104.
      View in: PubMed
    138. Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003 Mar 01; 21(5):878-83. PMID: 12610188.
      View in: PubMed
    139. Shaw PH, Gilligan D, Wang XM, Thall PF, Corey SJ. Ex vivo expansion of megakaryocyte precursors from umbilical cord blood CD34 cells in a closed liquid culture system. Biol Blood Marrow Transplant. 2003 Mar; 9(3):151-6. PMID: 12652464.
      View in: PubMed
    140. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer. 2003 Feb 01; 97(3):561-7. PMID: 12548597.
      View in: PubMed
    141. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood. 2003 Jul 15; 102(2):442-8. PMID: 12560224.
      View in: PubMed
    142. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol. 2003 Jan; 88(1):73-9. PMID: 12504632.
      View in: PubMed
    143. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002 Dec; 58(4):823-31. PMID: 12495136.
      View in: PubMed
    144. Thall PF. Ethical issues in oncology biostatistics. Stat Methods Med Res. 2002 Oct; 11(5):429-48. PMID: 12357588.
      View in: PubMed
    145. Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002 Sep; 58(3):560-8. PMID: 12229990.
      View in: PubMed
    146. Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer. 2002 Aug 15; 95(4):758-65. PMID: 12209719.
      View in: PubMed
    147. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002 Jul 15; 20(14):3072-80. PMID: 12118020.
      View in: PubMed
    148. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002 Jun 15; 99(12):4343-9. PMID: 12036860.
      View in: PubMed
    149. Faderl S, Thall PF, Kantarjian HM, Estrov Z. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol. 2002 Jun; 117(4):869-74. PMID: 12060122.
      View in: PubMed
    150. Cheung YK, Thall PF. Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics. 2002 Mar; 58(1):89-97. PMID: 11890331.
      View in: PubMed
    151. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002; 8(9):477-85. PMID: 12374452.
      View in: PubMed
    152. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001 Dec 15; 98(13):3575-83. PMID: 11739159.
      View in: PubMed
    153. Stallard N, Thall PF. Decision-theoretic designs for pre-phase II screening trials in oncology. Biometrics. 2001 Dec; 57(4):1089-95. PMID: 11764248.
      View in: PubMed
    154. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001 Nov 01; 92(9):2364-73. PMID: 11745292.
      View in: PubMed
    155. Thall PF, Sung HG, Choudhury A. Dose-finding based on feasibility and toxicity in T-cell infusion trials. Biometrics. 2001 Sep; 57(3):914-21. PMID: 11550945.
      View in: PubMed
    156. Thall PF, Cheng SC. Optimal two-stage designs for clinical trials based on safety and efficacy. Stat Med. 2001 Apr 15; 20(7):1023-32. PMID: 11276033.
      View in: PubMed
    157. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7. PMID: 11157478.
      View in: PubMed
    158. Seong CM, Giralt S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall P, Siciliano MJ, Champlin RE. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol. 2000 May; 18(9):1831-6. PMID: 10784623.
      View in: PubMed
    159. Thall PF, Millikan RE, Sung HG. Evaluating multiple treatment courses in clinical trials. Stat Med. 2000 Apr 30; 19(8):1011-28. PMID: 10790677.
      View in: PubMed
    160. Dougherty TB, Porche VH, Thall PF. Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for postoperative analgesia. Anesthesiology. 2000 Apr; 92(4):1010-6. PMID: 10754620.
      View in: PubMed
    161. Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects. Biometrics. 2000 Mar; 56(1):213-9. PMID: 10783798.
      View in: PubMed
    162. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood. 2000 Jan 01; 95(1):72-7. PMID: 10607687.
      View in: PubMed
    163. Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer. 1999 Dec 01; 86(11):2291-300. PMID: 10590370.
      View in: PubMed
    164. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec; 5(12):4041-7. PMID: 10632337.
      View in: PubMed
    165. Stallard N, Thall PF, Whitehead J. Decision theoretic designs for phase II clinical trials with multiple outcomes. Biometrics. 1999 Sep; 55(3):971-7. PMID: 11315037.
      View in: PubMed
    166. Thall PF, Cheng SC. Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. Biometrics. 1999 Sep; 55(3):746-53. PMID: 11315002.
      View in: PubMed
    167. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66. PMID: 10430080.
      View in: PubMed
    168. Estey EH, Thall PF, Reed P, Kantarjian H, Beran M, Pierce S, Keating MJ. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia. 1999 Jun; 13(6):850-4. PMID: 10360371.
      View in: PubMed
    169. Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. Stat Med. 1999 May 30; 18(10):1155-69. PMID: 10363337.
      View in: PubMed
    170. Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Körbling M, Deisseroth AB, Champlin R. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81. PMID: 10373061.
      View in: PubMed
    171. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999 Apr 15; 93(8):2478-84. PMID: 10194425.
      View in: PubMed
    172. Thall PF, Estey EH, Sung HG. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Invest New Drugs. 1999; 17(2):155-67. PMID: 10638486.
      View in: PubMed
    173. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 01; 92(9):3090-7. PMID: 9787143.
      View in: PubMed
    174. Price KJ, Thall PF, Kish SK, Shannon VR, Andersson BS. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med. 1998 Sep; 158(3):876-84. PMID: 9731020.
      View in: PubMed
    175. Wright-Browne V, Schnee AM, Jenkins MA, Thall PF, Aggarwal BB, Talpaz M, Estrov Z. Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. Leuk Lymphoma. 1998 Aug; 30(5-6):583-9. PMID: 9711920.
      View in: PubMed
    176. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med. 1998 Jul 30; 17(14):1563-80. PMID: 9699230.
      View in: PubMed
    177. Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med. 1998 May 15; 17(9):999-1015. PMID: 9612887.
      View in: PubMed
    178. Seong D, Thall P, Kantarjian HM, Talpaz M, Swantkowski J, Xu J, Shen Y, Glassman A, Ramagli L, Siciliano MJ. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. Clin Cancer Res. 1998 Apr; 4(4):861-7. PMID: 9563879.
      View in: PubMed
    179. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics. 1998 Mar; 54(1):251-64. PMID: 9544520.
      View in: PubMed
    180. Staniswalis JG, Thall PF, Salch J. Semiparametric regression analysis for recurrent event interval counts. Biometrics. 1997 Dec; 53(4):1334-53. PMID: 9423253.
      View in: PubMed
    181. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997 Oct 15; 90(8):2969-77. PMID: 9376577.
      View in: PubMed
    182. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997 Oct; 11(10):1661-4. PMID: 9324286.
      View in: PubMed
    183. van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6. PMID: 9310192.
      View in: PubMed
    184. Spector N, Pulcheri W, Nucci M, Maiolino A. Comparing an apple to a fruit salad. J Clin Oncol. 1997 Aug; 15(8):3021-2. PMID: 9256146.
      View in: PubMed
    185. O'Brien S, Thall PF, Siciliano MJ. Cytogenetics of chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997 Jun; 10(2):259-76. PMID: 9376663.
      View in: PubMed
    186. Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Körbling M. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60. PMID: 9052911.
      View in: PubMed
    187. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol. 1997 Feb; 15(2):483-90. PMID: 9053469.
      View in: PubMed
    188. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 1997; 40 Suppl:S9-12. PMID: 9272127.
      View in: PubMed
    189. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15346-51. PMID: 8986814; PMCID: PMC26407.
    190. Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood. 1996 May 01; 87(9):3650-4. PMID: 8611689.
      View in: PubMed
    191. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol. 1996 Jan; 14(1):296-303. PMID: 8558211.
      View in: PubMed
    192. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996 Jan; 27(1):65-73. PMID: 8699228.
      View in: PubMed
    193. Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia. 1995 Oct; 9(10):1735-41. PMID: 7564518.
      View in: PubMed
    194. Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1995 Sep 30; 33(2):357-64. PMID: 7673023.
      View in: PubMed
    195. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995 Feb 28; 14(4):357-79. PMID: 7746977.
      View in: PubMed
    196. Thall PF, Simon RM. Recent developments in the design of phase II clinical trials. Cancer Treat Res. 1995; 75:49-71. PMID: 7640167.
      View in: PubMed
    197. Thall PF, Simon R. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Control Clin Trials. 1994 Dec; 15(6):463-81. PMID: 7851108.
      View in: PubMed
    198. Ensign LG, Gehan EA, Kamen DS, Thall PF. An optimal three-stage design for phase II clinical trials. Stat Med. 1994 Sep 15; 13(17):1727-36. PMID: 7997706.
      View in: PubMed
    199. Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics. 1994 Jun; 50(2):337-49. PMID: 7980801.
      View in: PubMed
    200. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994 Apr; 12(4):671-8. PMID: 7512125.
      View in: PubMed
    201. Simon R, Thall PF, Ellenberg SS. New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med. 1994 Mar 15-Apr 15; 13(5-7):417-29. PMID: 8023026.
      View in: PubMed
    202. Thall PF, Estey EH. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Stat Med. 1993 Jul 15; 12(13):1197-211. PMID: 8210822.
      View in: PubMed
    203. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood. 1992 May 01; 79(9):2246-55. PMID: 1571541.
      View in: PubMed
    204. Thall PF, Vail SC. Some covariance models for longitudinal count data with overdispersion. Biometrics. 1990 Sep; 46(3):657-71. PMID: 2242408.
      View in: PubMed
    205. Thall PF, Simon R. Incorporating historical control data in planning phase II clinical trials. Stat Med. 1990 Mar; 9(3):215-28. PMID: 2188324.
      View in: PubMed
    206. Halperin M, Hamdy MI, Thall PF. Distribution-free confidence intervals for a parameter of Wilcoxon-Mann-Whitney type for ordered categories and progressive censoring. Biometrics. 1989 Jun; 45(2):509-21. PMID: 2765635.
      View in: PubMed
    207. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics. 1989 Jun; 45(2):537-47. PMID: 2765637.
      View in: PubMed
    208. Thall PF, Simon R, Ellenberg SS, Shrager R. Optimal two-stage designs for clinical trials with binary response. Stat Med. 1988 May; 7(5):571-9. PMID: 3387716.
      View in: PubMed
    209. Thall PF. Mixed Poisson likelihood regression models for longitudinal interval count data. Biometrics. 1988 Mar; 44(1):197-209. PMID: 3358988.
      View in: PubMed
    210. Thall PF, Lachin JM. Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. Stat Med. 1986 Jan-Feb; 5(1):73-83. PMID: 3515475.
      View in: PubMed
    211. Estimating genomic category probabilities from fluorescent in situ hybridization counts with misclassification. Journal of the Royal Statistical Society. Series C: Applied Statistics. 45:431-446.
    212. Dose-Finding Based on Multiple Ordinal Toxicities in Phase I Oncology Trials. 243-258.
    213. Discussion on "a hybrid selection and testing procedure with curtailment for comparative clinical trials" by Elena M. Buzaianu and Pinyuen Chen. Sequential Analysis. 28:41-43.
    214. Evaluating joint effects of induction-salvage treatment regimes on overall survival in acute leukaemia. Journal of the Royal Statistical Society. Series C: Applied Statistics. 62:67-83.
    215. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. Journal of the American Statistical Association. 107:493-508.
    216. Analysis of recurrent events based on random interval count data. Controlled Clinical Trials. 7:237.
    217. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. Journal of Thoracic Oncology. 10:518-526.
    218. A Bayesian hierarchical mixture model for platelet-derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. Journal of the Royal Statistical Society. Series C: Applied Statistics. 59:19-34.
    219. Two-stage selection and testing designs for comparative clinical trials. Biometrika. 75:303-310.
    220. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    221. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation.
    222. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation. 50:939-946.
    223. Evaluating the impact of prior assumptions in Bayesian biostatistics. Statistics in Biosciences. 2:1-17.
    224. A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics. 17:304-319.
    225. Bayesian models and decision algorithms for complex early phase clinical trials. Statistical Science. 25:227-244.
    226. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. Journal of the Royal Statistical Society. Series C: Applied Statistics. 61:135-149.
    227. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiotherapy and Oncology. 121:70-74.
    228. A modified adaptive Lasso for identifying interactions in the Cox model with the heredity constraint. Statistics and Probability Letters. 93:126-133.
    229. Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times. Journal of the American Statistical Association. 111:921-950.
    230. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.
    231. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia.
    232. Reply from authors re. European Urology. 62:1022.
    233. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors. Journal of Neuro-Oncology. 125:133-141.
    234. A theorem on regular infinitely divisible cox processes. Stochastic Processes and their Applications. 16:205-210.
    235. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21:1392-1398.
    236. Bayesian group sequential clinical trial design using total toxicity burden and progression-free survival. Journal of the Royal Statistical Society. Series C: Applied Statistics. 65:273-297.
    237. Optimal two-stage designs for clinical trials with binary response. Controlled Clinical Trials. 9:252.
    238. Letter to the editors. Clinical Advances in Hematology and Oncology. 4:95.
    239. Variable selection in regression via repeated data splitting. Journal of Computational and Graphical Statistics. 6:416-434.
    240. COUNT DISTRIBUTIONS, ORDERLINESS AND INVARIANCE OF POISSON CLUSTER PROCESSES. Journal of Applied Probability. 16:261-273.
    241. Score tests in the two-way layout of counts. Communications in Statistics - Theory and Methods. 21:3017-3036.
    242. Utility-based designs for randomized comparative trials with categorical outcomes. Statistics in Medicine. 35:4285-4305.
    243. Huber-sense robust M-estimation of a scale parameter, with application to the exponential distribution. Journal of the American Statistical Association. 74:147-152.
    244. Using Both Efficacy and Toxicity for Dose-Finding. 275-285.
    245. Analysis of recurrent events. Journal of the American Statistical Association. 83:339-347.
    246. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy (Proceedings of the National Academy of Sciences (December 24, 1996) 93 (15346-15351)). Proceedings of the National Academy of Sciences of the United States of America. 94:5495.
    247. Selecting therapeutic strategies based on efficacy and death in multicourse clinical trials. Journal of the American Statistical Association. 97:29-39.
    248. Comments on 'Continuous Bayesian adaptive randomization based on event times with covariates' [4]. Statistics in Medicine. 26:3052-3054.
    249. Test-Based Variable Selection Via Cross-Validation. Journal of Computational and Graphical Statistics. 1:41-61.
    250. A Two-Stage Design for Dose-Finding with Two Agents. 259-274.
    251. A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity. Journal of Statistical Planning and Inference. 142:944-955.
    252. Response. Journal of the National Cancer Institute. 100:682-683.
    253. Bayesian guidelines for phase II clinical trial design and analysis. Controlled Clinical Trials. 13:377.
    254. Journal of the American Statistical Association. 109:525-536.
    255. Statistical controversies in clinical research. Annals of Oncology. 26:1621-1628.
    256. Some geometric methods for constructing decision criteria based on two-dimensional parameters. Journal of Statistical Planning and Inference. 138:516-527.
    257. Rejoinder. Journal of the American Statistical Association. 111:948-950.
    258. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity. Journal of the American Statistical Association. 110:711-722.
    259. Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. Journal of the American Statistical Association. 109:931-943.
    260. Rejoinder. Journal of the American Statistical Association. 107:518-520.
    261. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data. Statistics in Medicine. 34:3424-3443.
    262. An explanation of generalized profile likelihoods. Statistics and Computing. 11:293-298.
    263. Parametric dose standardization for optimizing two-agent combinations in a phase I-II trial with ordinal outcomes. Journal of the Royal Statistical Society. Series C: Applied Statistics.
    264. Biology of Blood and Marrow Transplantation. 22:1792-1800.
    265. Prior effective sample size in conditionally independent hierarchical models. Bayesian Analysis. 7:591-614.
    266. Clinical trial design as a decision problem. Applied Stochastic Models in Business and Industry.
    267. On the structure of regular infinitely divisible point processes. Stochastic Processes and their Applications. 6:87-94.
    268. Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial. Journal of the American Statistical Association. 99:26-35.
    THALL's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description